These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12589577)

  • 1. An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
    Archer T; Fredriksson A
    J Neural Transm (Vienna); 2003 Feb; 110(2):183-200. PubMed ID: 12589577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
    Fredriksson A; Palomo T; Archer T
    J Neural Transm (Vienna); 1999; 106(9-10):889-909. PubMed ID: 10599871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
    Fredriksson A; Danysz W; Quack G; Archer T
    J Neural Transm (Vienna); 2001; 108(2):167-87. PubMed ID: 11314771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of riluzole in MPTP-treated mice.
    Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
    Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal iron overload destroys NA-DA functional interactions.
    Fredriksson A; Archer T
    J Neural Transm (Vienna); 2007 Feb; 114(2):195-203. PubMed ID: 16932993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restorative effects of glutamate antagonists in experimental parkinsonism.
    Archer T; Palomo T; Fredriksson A
    Amino Acids; 2002; 23(1-3):71-85. PubMed ID: 12373521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
    Fredriksson A; Archer T
    Behav Brain Res; 2003 Feb; 139(1-2):31-46. PubMed ID: 12642174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa.
    Fredriksson A; Palomo T; Archer T
    Behav Pharmacol; 2000 Nov; 11(7-8):571-81. PubMed ID: 11198128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice.
    Obuchowicz E; Antkiewicz-Michaluk L; Romańska I; Herman ZS
    J Neural Transm (Vienna); 2003 Dec; 110(12):1375-91. PubMed ID: 14666410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
    Dethy S; Laute MA; Damhaut P; Goldman S
    J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
    Morgan WW; Nelson JF
    Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
    Fredriksson A; Archer T
    Amino Acids; 2002; 23(1-3):111-32. PubMed ID: 12373526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration and putative protection in Parkinsonism.
    Archer T; Fredriksson A
    Neurotox Res; 2000; 2(2-3):251-92. PubMed ID: 16787845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model].
    Kucherianu VG
    Eksp Klin Farmakol; 2001; 64(1):22-5. PubMed ID: 11544797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
    Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD
    Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
    Fredriksson A; Palomo T; Chase T; Archer T
    J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.